Featured Research

from universities, journals, and other organizations

New psoriasis drug shows potential

Date:
July 16, 2014
Source:
University of Alabama at Birmingham
Summary:
Secukinumab is a safe and effective psoriasis treatment, a new study concludes. Affecting more than 3 percent of people in the United States, psoriasis can go beyond the physical and also affect mental health.

Randomized, phase III research from the University of Alabama at Birmingham shows that a new drug improves symptoms related to moderate to severe plaque psoriasis, a chronic skin disease of scaling and inflammation.

Related Articles


Affecting more than 3 percent of people in the United States, psoriasis can go beyond the physical and also affect mental health, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Boni E. Elewski, M.D., professor of dermatology, is the principal investigator of the Efficacy of Response And Safety of two fixed secUkinumab REgimens in psoriasis (ERASURE) trial, one of two studies in the recent New England Journal of Medicine article "Secukinumab in Plaque Psoriasis -- Results of Two Phase 3 Trials."

"The combined results of ERASURE, along with the FIXTURE trial, are very exciting in terms of the efficacy and safety of secukinumab," Elewski, co-lead author, said.

ERASURE compared the drug to placebo, while FIXTURE compared it to placebo and another psoriasis treatment -- etanercept. Both trials assessed the efficacy, safety and tolerability of secukinumab. Together, the trials are part of the largest phase III program in moderate to severe plaque psoriasis completed to date, which involved more than 3,300 patients in more than 35 countries.

"We found that a statistically significant percentage of secukinumab-treated moderate to severe psoriasis patients achieved an up to 90 percent skin clearance after 12 weeks, and with continued treatment, a majority of these patients had maintained those results at 52 weeks," Elewski said.

Elewski says both trials confirmed earlier findings from basic research and phase II trials of secukinumab.

"These results' being published in NEJM validates the significance of the studies and will hopefully draw attention to the major unmet need of this disease," Elewski said. "If approved, having a safe and effective drug like secukinumab would be amazing, and it will greatly improve the quality of life for psoriasis patients, many of whom are dissatisfied with existing therapies."


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard G. Langley, Boni E. Elewski, Mark Lebwohl, Kristian Reich, Christopher E.M. Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson, Enrique Rivas, Tsen-Fang Tsai, Norman Wasel, Stephen Tyring, Thomas Salko, Isabelle Hampele, Marianne Notter, Alexander Karpov, Silvia Helou, Charis Papavassilis. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. New England Journal of Medicine, 2014; 140710084619009 DOI: 10.1056/NEJMoa1314258

Cite This Page:

University of Alabama at Birmingham. "New psoriasis drug shows potential." ScienceDaily. ScienceDaily, 16 July 2014. <www.sciencedaily.com/releases/2014/07/140716214910.htm>.
University of Alabama at Birmingham. (2014, July 16). New psoriasis drug shows potential. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2014/07/140716214910.htm
University of Alabama at Birmingham. "New psoriasis drug shows potential." ScienceDaily. www.sciencedaily.com/releases/2014/07/140716214910.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Suicide Rates Up For Young Women In U.S.

Suicide Rates Up For Young Women In U.S.

Newsy (Mar. 6, 2015) — According to a report from the CDC, suicide rates among young women increased from 1994 to 2012 while rates among young men have decreased. Video provided by Newsy
Powered by NewsLook.com
Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) — Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Liberia Releases Last Ebola Patient, But Threat Remains

Liberia Releases Last Ebola Patient, But Threat Remains

Newsy (Mar. 5, 2015) — Liberia&apos;s last Ebola patient has been released, and the country hasn&apos;t recorded a new case in a week. However, fears of another outbreak still exist. Video provided by Newsy
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) — Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins